Gilead Sciences (GILD) : Capital Management Corp Va reduced its stake in Gilead Sciences by 8.32% during the most recent quarter end. The investment management company now holds a total of 105,231 shares of Gilead Sciences which is valued at $9,107,743 after selling 9,544 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Jul 20, 2016.Gilead Sciences makes up approximately 3.35% of Capital Management Corp Va’s portfolio.
Other Hedge Funds, Including , First American Bank reduced its stake in GILD by selling 22,273 shares or 18.22% in the most recent quarter. The Hedge Fund company now holds 100,005 shares of GILD which is valued at $8,655,433. Gilead Sciences makes up approx 0.85% of First American Bank’s portfolio.Mechanics Bank Trust Department boosted its stake in GILD in the latest quarter, The investment management firm added 445 additional shares and now holds a total of 7,551 shares of Gilead Sciences which is valued at $654,370. Gilead Sciences makes up approx 0.23% of Mechanics Bank Trust Department’s portfolio.Mitchell Mcleod Pugh Williams Inc reduced its stake in GILD by selling 2,220 shares or 14.73% in the most recent quarter. The Hedge Fund company now holds 12,850 shares of GILD which is valued at $1,117,051. Gilead Sciences makes up approx 0.83% of Mitchell Mcleod Pugh Williams Inc’s portfolio.Boulegeris Investments boosted its stake in GILD in the latest quarter, The investment management firm added 235 additional shares and now holds a total of 73,361 shares of Gilead Sciences which is valued at $6,290,706. Gilead Sciences makes up approx 4.16% of Boulegeris Investments’s portfolio.Gateway Investment Advisers reduced its stake in GILD by selling 102,838 shares or 9.86% in the most recent quarter. The Hedge Fund company now holds 939,808 shares of GILD which is valued at $80,588,536. Gilead Sciences makes up approx 0.68% of Gateway Investment Advisers’s portfolio.
Gilead Sciences opened for trading at $85.46 and hit $87.12 on the upside on Wednesday, eventually ending the session at $86.66, with a gain of 1.43% or 1.22 points. The heightened volatility saw the trading volume jump to 90,55,877 shares. Company has a market cap of $115,416 M.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Gabelli & Co Initiated Gilead Sciences on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $109.Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.